Winter, 2023 | Number 1, Volume 37
Some cases of autism may involve mutations in a gene called MYT1L, according to new research by Bettina Weigel and colleagues.
Weigel and her team studied the role of MYT1L—called the “guardian of neuronal identity,” because it is one of three genes needed to turn stem cells into neurons rather than other types of cells—by exploring the effects of MYT1L deficiency both in mice and in human nerve cells derived from reprogrammed stem cells in the laboratory.
The researchers found that mice deficient in MYT1L had a thinner cerebral cortex. The mice also exhibited several behavioral changes similar to those seen in autism, including social deficits (seen only in male mice) and hyperactivity. MYT1L mutations may play a role in some cases of autism.
Additionally, the neurons of MYT1Ldeficient mice produced an excess of sodium channels, leading to electrophysiological hyperactivation and impairing nerve function. Treatment with lamotrigine, an anti-epileptic drug that blocks sodium channels, returned the cells’ electrophysiological activity to normal, and MYT1L-deficient mice given the drug no longer exhibited hyperactivity or anxiety-like behaviors.
The researchers discovered that in the MYT1L-deficient mouse neurons, as well as in human nerve cells engineered to be deficient in MYT1L, genes that prompt cells into becoming muscle or heart tissue were still active. This indicates, Mall says, that “[t]he cells cannot jump from the progenitor stage that efficiently to a differentiated neural state.”
Weigel and colleagues note that while lamotrigine reduced hyperactivity and anxiety-related behaviors in mice, it is not yet known if it may be helpful for humans with ASD associated with MYT1L mutations. A 2001 study by Karin Belsito and colleagues found that lamotrigine did not improve the scores of children with ASD on standardized behavior tests.
“MYT1L haploinsufficiency in human neurons and mice causes autism-associated phenotypes that can be reversed by genetic and pharmacologic intervention,” Bettina Weigel, Jana F. Tegethoff, Sarah D. Grieder, Bryce Lim, Bhuvaneswari Nagarajan, Yu-Chao Liu, Jule Truberg, Dimitris Papageorgiou, Juan M. Adrian-Segarra, Laura K. Schmidt, Janina Kaspar, Eric Poisel, Elisa Heinzelmann, Manu Saraswat, Marleen Christ, Christian Arnold, Ignacio L. Ibarra, Joaquin Campos, Jeroen Krijgsveld, Hannah Monyer, Judith B. Zaugg, Claudio Acuna, and Moritz Mall, Molecular Psychiatry, February 14, 2023 (free online). Address: Moritz Mall, [email protected].
—and—
“Autism-linked MYT1L mutations prompt ‘identify crisis’ in budding brain cells,” Laura Dattaro, Spectrum News, February 14, 2023.
—see also—
“Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial,” Karin M. Belsito, Paul A. Law, Karen S. Kirk, Rebecca J. Landa, and Andrew W. Zimmerman, Journal of Autism and Developmental Disorders, April 2001 (online). Address: Karin Belsito, [email protected]